<DOC>
	<DOCNO>NCT01788280</DOCNO>
	<brief_summary>This exploratory study use [ 18F ] Fluciclatide Positron emission tomography ( PET ) image patient glioblastoma multiforme ( GBM ) treat Bevacizumab . The primary objective study determine association [ 18F ] Fluciclatide uptake , fludeoxyglucose ( FDG ) uptake , tumor blood flow/perfusion determine H215O Magnetic resonance imaging ( MRI ) correlate variable time progression ( TTP ) participant GBM treat Bevacizumab .</brief_summary>
	<brief_title>Preliminary Assessment 18F Fluciclatide ( GE 18FAH111585 ) Glioblastoma Multiforme Treated With Bevacizumab</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients must 18 year old inclusion research study . There inadequate experience safety [ 18F ] Fluciclatide ( GE [ 18F ] AH111585 ) child therefore radiopharmaceutical use patient age 18 . The patient must histologically prove GBM , schedule treat Avastin therapy . Patient tumor volume &gt; 2.0 cm great diameter require assess response therapy . An anatomic imaging study ( MRI brain ) must current obtain within 28 day prior research PET image study . Patients must agree clinical radiographic endpoint result histopathologic tissue analysis laboratory information enter research database , evidence signing informed consent form . All patient , legal guardian , must sign write informed consent HIPAA authorization accordance institutional guideline . If patient female , must postmenopausal minimum one year , surgically sterile , confirm pregnant serum pregnancy test perform within 48 hour prior research PET imaging . Patient must lactate . Pretreatment laboratory test patient receive [ 18F ] Fluciclatide ( GE [ 18F ] AH111585 ) must perform within 21 day prior study entry . These laboratory test must less 4.0 time upper low limit range respective laboratory test entry study ( unless medically clinically relevant ) . For patient receive coumadin another anticoagulant upper limit prothrombin time partial thromboplastin time must exceed 6 time upper limit normal range . Urinalysis abnormalities preclude patient enrol study . The laboratory test include liver enzyme ( SGOT , SGPT , ALK Phos , GGT , LDH ) , bilirubin ( total ) , amylase , albumin , serum electrolyte ( sodium , potassium , chloride , HCO3 , calcium , creatinine , urea nitrogen , glucose ) CBC platelets prothrombin time , partial thromboplastin time , BUN , creatinine urinalysis ( screen ) . Patients know allergic hypersensitivity reaction previously administer radiopharmaceutical . Patients significant drug allergy autoimmune disease may enrol Investigator 's discretion . Adult patient require monitored anesthesia PET scanning . Patients claustrophobic undergo MRI PET image . Patients calculate GFR le 30 ml/min exclude study . For GFR 3060 ml/min MRI possible ( use half usual administer dose contrast ) discretion study doctor . If patient wish undergo MRI due renal function exclude study . Patients know HIV positive . This due unknown potential toxicity Fluciclatide HIV positive patient . Patients undergo MRI imaging due MRI exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>